EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Gilead Sciences Inc (GILD): Today's Featured Drugs Loser

By TheStreet Wire 07/05/12 - 05:01 PM EDT

Find out if (GILD) is in Cramer's Portfolio.

Gilead (GILD) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.7%. By the end of trading, Gilead fell 62 cents (-1.2%) to $51.46 on light volume. Throughout the day, 3.1 million shares of Gilead exchanged hands as compared to its average daily volume of 6.3 million shares. The stock ranged in price between $51.34-$52.15 after having opened the day at $52.03 as compared to the previous trading day's close of $52.08. Other company's within the Drugs industry that declined today were: Natural Alternatives International (NAII), down 15%, Cardiome Pharma Corporation (CRME), down 13.2%, Telik (TELK), down 11.3%, and Cormedix (CRMD), down 10%.

ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $39.44 billion and is part of the health care sector. The company has a P/E ratio of 15.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 27.2% year to date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

You can view the full Gilead Ratings Report.

On the positive front, Medgenics (MDGN), up 43%, Rexahn Pharmaceuticals (RNN), up 29.5%, EntreMed (ENMD), up 24%, and Coronado Biosciences (CNDO), up 20%, were all gainers within the drugs industry with Herbalife (HLF) being today's featured drugs industry winner.

Use our drugs section to find industry-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Find other investment ideas from our top rated ETFs lists.

For more information on Gilead Sciences Inc click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.